Bioequivalence (BE) Study Between YHP2511 and YHP2511A in Healthy Volunteers
← catalyst calendarSponsored by Yuhan Corporation (industry) · 000100.KS — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
61actual
Sites
1
Country
South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-23 | actual | When the study began enrolling |
| Primary completion | 2026-07-11 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-20 | actual | The whole study's end, after follow-up |
| First posted | 2026-03-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Subjects
Interventions
- Drug: YHP2511
- Drug: YHP2511A
Primary outcomes
what the primary-completion date above is the date OFArea under the plasma drug concentration-time curve [AUCt]
measured Pitavastatin : 0-72 hours, Total Ezetimibe: 0-72 hours
Maximum plasma concentration [Cmax]
measured Pitavastatin: 0-48 hours, Total Ezetimibe: 0-72 hours
Permalink · 000100.KS's whole pipeline · Catalyst calendar · Every registered study · What changed